RT Journal Article
T1 Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort
A1 Fortner, Renée T
A1 Sarink, Danja
A1 Schock, Helena
A1 Johnson, Theron
A1 Tjønneland, Anne
A1 Olsen, Anja
A1 Overvad, Kim
A1 Affret, Aurélie
A1 His, Mathilde
A1 Boutron-Ruault, Marie-Christine
A1 Boeing, Heiner
A1 Trichopoulou, Antonia
A1 Naska, Androniki
A1 Orfanos, Philippos
A1 Palli, Domenico
A1 Sieri, Sabina
A1 Mattiello, Amalia
A1 Tumino, Rosario
A1 Ricceri, Fulvio
A1 Bueno-de-Mesquita, H Bas
A1 Peeters, Petra H M
A1 Van Gils, Carla H
A1 Weiderpass, Elisabete
A1 Lund, Eiliv
A1 Quirós, J Ramón
A1 Agudo, Antonio
A1 Sanchez-Perez, Maria-Jose
A1 Chirlaque, María-Dolores
A1 Ardanaz, Eva
A1 Dorronsoro, Miren
A1 Key, Tim
A1 Khaw, Kay-Tee
A1 Rinaldi, Sabina
A1 Dossus, Laure
A1 Gunter, Marc
A1 Merritt, Melissa A
A1 Riboli, Elio
A1 Kaaks, Rudolf
K1 Breast cancer
K1 Neoplasias de la mama
K1 Estrogen receptor
K1 Hormone receptor
K1 Osteoprotegerin
K1 Osteoprotegerina
K1 Progesterone receptor
K1 Receptores de progesterona
K1 Receptores estrogénicos
K1 Receptores de hormonas
K1 RANK axis
AB BACKGROUND:Circulating osteoprotegerin (OPG), a member of the receptor activator of nuclear factor kappa-B (RANK) axis, may influence breast cancer risk via its role as the decoy receptor for both the RANK ligand (RANKL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Circulating OPG and breast cancer risk has been examined in only one prior study.METHODS:A case-control study was nested in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. A total of 2008 incident invasive breast cancer cases (estrogen receptor (ER)+, n = 1622; ER-, n = 386), matched 1:1 to controls, were included in the analysis. Women were predominantly postmenopausal at blood collection (77%); postmenopausal women included users and non-users of postmenopausal hormone therapy (HT). Serum OPG was quantified with an electrochemiluminescence assay. Relative risks (RRs) and 95% confidence intervals (CIs) were calculated using conditional logistic regression.RESULTS:The associations between OPG and ER+ and ER- breast cancer differed significantly. Higher concentrations of OPG were associated with increased risk of ER- breast cancer (top vs. bottom tertile RR = 1.93 [95% CI 1.24-3.02]; p trend = 0.03). We observed a suggestive inverse association for ER+ disease overall and among women premenopausal at blood collection. Results for ER- disease did not differ by menopausal status at blood collection (p het = 0.97), and we observed no heterogeneity by HT use at blood collection (p het ≥ 0.43) or age at breast cancer diagnosis (p het ≥ 0.30).CONCLUSIONS:This study provides the first prospective data on OPG and breast cancer risk by hormone receptor subtype. High circulating OPG may represent a novel risk factor for ER- breast cancer.
PB BioMed Central
YR 2017
FD 2017-02-08
LK http://hdl.handle.net/10668/2647
UL http://hdl.handle.net/10668/2647
LA en
NO Fortner R, Sarink D, Schock H, Johnson T, Tjønneland A, Olsen A et al. Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort. BMC Medicine. 2017;15(1)
DS RISalud
RD Apr 10, 2025